Prothea Technologies ("Prothea"), a private medical technology company spun-out of the Universities of Edinburgh and Bath with a vision to offer lung cancer biopsy and treatment in a single hospital visit, launched with a EUR 12 million Series A funding round.
The round was co-led by Earlybird Venture Capital and Merieux Equity Partners, with participation from NRW.BANK and Old College Capital.
International legal practice Osborne Clarke advised lead investors Earlybird and Merieux Equity Partners, together with NRW.BANK. The team was led by venture and growth capital partner Justin Starling and legal director Elizabeth Yell with the support of legal director Elizabeth Shanahan and associate Amy Moylett.
Prothea has in-licensed several patents from the Universities of Edinburgh and Bath and this fundraising round will finance Prothea's First-In-Human (FIH) lung cancer clinical trial for its real-time imaging catheter and initiate the FIH for its therapeutic ablation catheter.
Osborne Clarke's international venture capital team is a leading adviser from start-up through venture financing and the growth journey beyond, whether continuing to sale, IPO or international expansion. The team has an outstanding track record advising businesses, entrepreneurs and investors that are driving innovation. Osborne Clarke's dedicated resource centre, OC Ventures, brings together experts from across our international network to deliver a seamless service to clients throughout the ventures ecosystem.
Corporate communications and press contacts
Connect with one of our experts
